

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Cornerstone Therapeutics Inc.	08/03/2011
RECEIVING PARTY DATA	
Name:	The Feinstein Institute for Medical Research
Street Address:	350 Community Drive
City:	Manhasset
State/Country:	NEW YORK
Postal Code:	11030
PROPERTY NUMBERS Total: 17	
Property Type	Number
Application Number:	60427846
PCT Number:	US0337507
Application Number:	11632257
Application Number:	12840410
Application Number:	60589678
Application Number:	11186422
PCT Number:	US0525877
Application Number:	12313504
Application Number:	60502568
Application Number:	10938992
PCT Number:	US0429527
Application Number:	11903129
Application Number:	11974923
Application Number:	12897453
Application Number:	60700704

501622385

PATENT
REEL: 026728 FRAME: 0733

CH \$680.00 60427846

PCT Number:	US0627503
Application Number:	11988896
CORRESPONDENCE DATA Fax Number: (212)336-8001 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> Phone: 212 336 8000 Email: ptodocket@arelaw.com Correspondent Name: Amster, Rothstein & Ebenstein LLP Address Line 1: 90 Park Avenue Address Line 4: New York, NEW YORK 10016	
ATTORNEY DOCKET NUMBER:	50425/92
NAME OF SUBMITTER:	Alan D. Miller
Total Attachments: 4 source=assignment#page1.tif source=assignment#page2.tif source=assignment#page3.tif source=assignment#page4.tif	

PATENT ASSIGNMENT

WHEREAS, Cornerstone Therapeutics Inc. (hereinafter "the Assignor"), having a principal place of business at 1255 Crescent Green Drive, Suite 250, Cary, North Carolina 27518, U.S.A., has an interest in the patent applications and patents listed in the attached Appendix, and the inventions described therein, and each and every patent that can be issued on said applications and on said invention in the United States of America and in its territorial possessions, and in all countries and regions foreign to the United States of America; and

WHEREAS, The Feinstein Institute for Medical Research (hereinafter "the Assignee"), having a principal place of business at 350 Community Drive, Manhasset, New York 11030, U.S.A., is desirous of acquiring the Assignor's entire right, title and interest in and to said applications and patents and the inventions described therein, and each and every patent that can be issued on said applications and on said inventions in the United States of America and in its territorial possessions, and in all countries and regions foreign to the United States of America;

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN, be it known that for good and valuable consideration, the receipt of which is hereby acknowledged, the Assignor hereby sells, assigns and transfers unto the Assignee its full and exclusive right, title and interest in and to the aforesaid applications and patents, the aforesaid inventions, and each and every patent that may be issued on the aforesaid inventions and applications in the United States of America, and in its territorial possessions and also in all countries and regions foreign to the United States of America, the same to be held and enjoyed by the Assignee for its own use and benefit, and for the use and benefit of its successors, assigns or other legal representatives to the end of the term or terms for which a patent or patents may be granted as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

Assignor hereby covenants that no assignment, sale, agreement, or encumbrance has been, or will be, made or entered into which would conflict with this Assignment.

Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks to issue any and all Letters Patent on the aforesaid inventions or resulting from the aforesaid applications directly to the Assignee.

Assignor further covenants to execute all additional instruments and to do all things necessary to carry out the purpose of this instrument, at the expense of the Assignee and its successors.

CORNERSTONE THERAPEUTICS INC.

By_

8/3/11

August 3, 2011

State of North Carolina }
County of Wake }
SS: }

Kelly Cunningham

Notary Public

Appendix

CRTX Docket number	HBSR Docket number	Application Title	Application number, filing date and priority	Inventor(s)
CTIP-012-P	3258.1008-000	HMGB1 Combination Therapies	60/427,846 11.20.02	Newman
CTIP-012-PCT	3258.1008-003	HMGB1 Combination Therapies	PCT/US03/37507 11.20.03 Priority to 60/427,846 and 60/427,841	Newman et al
CTIP-012-AU	3258.1008-004 AUSTRALIA	HMGB1 Combination Therapies	2003294488 11.20.03 National phase entry of PCT/US03/37507	Newman et al.
CTIP-012-NZ	3258.1008-008 NEW ZEALAND	HMGB1 Combination Therapies	540067 11.20.03 National phase entry of PCT/US03/37507	Newman et al.
CTIP-015-US	3258.1013-005	Combination therapy comprising inhibitor of HMGB biological activity and complement inhibitor	11/632,257 07.20.05 National stage entry of PCT/US2005/025799	Newman
CTIP-015-US-CON	3258.1013-006	Combination therapy comprising inhibitor of HMGB biological activity and complement inhibitor	12/840,410 07.21.10 Continuation of 11/632,257	Newman
CTIP-015-EU	3258.1013-004 EUROPE	Combination therapy comprising inhibitor of HMGB biological activity and complement inhibitor	05795481.0 11.20.05 National stage entry of PCT/US2005/025799	Newman
CTIP-016-P1	3258.1021-000	RAGE Protein Derivatives	60/589,678 07.20.04	O'Keefe
CTIP-016-US	3258.1021-001	RAGE Protein Derivatives	11/186,422 07.20.05 Priority to 60/589,678	O'Keefe
CTIP-016-PCT	3258.1021-003	RAGE Protein Derivatives	PCT/US2005/025877 07.20.05	O'Keefe
CTIP-016-EU	3258.1021-004 EUROPE	RAGE Protein Derivatives	05792020.9 07.20.05	O'Keefe
CTIP-016-US DIV1	3258.1021-005	RAGE Protein Derivatives	12/313,504 11.19.08 Divisional of 11/186,422	O'Keefe



CRTX Docket number	HBSR Docket number	Application Title	Application number, filing date and priority	Inventor(s)
CTIP-017-P1	3258.1033-000	Monoclonal antibodies against HMGB1	60/502,568 09.11.03	Newman et al.
CTIP-017-US	3258.1033-001	Monoclonal antibodies against HMGB1	10/938,992 09.10.04 Priority to 60/502,568	Newman et al.
CTIP-017-PCT	3258.1033-003 PCT	Monoclonal antibodies against HMGB1	PCT/US2004/029527 09.10.04 Priority to 60/502,568	Newman et al.
CTIP-017-AU	3258.1033-004 AUSTRALIA	Monoclonal antibodies against HMGB1	2004272607 09.10.04 National Stage entry of PCT/US2004/029527	Newman et al.
CTIP-017-CA	3258.1033-005 CANADA	Monoclonal antibodies against HMGB1	2538763 09.10.04 National Stage entry of PCT/US2004/029527	Newman et al.
CTIP-017-JP	3258.1033-007 JAPAN	Monoclonal antibodies against HMGB1	2006-526305 09.10.04 National Stage entry of PCT/US2004/029527	Newman et al.
CTIP-017-US DIV	3258.1033-010	Monoclonal antibodies against HMGB1	11/903,129 09.20.07 Divisional of 10/938,992	Newman et al.
CTIP-017-US C1	3258.1033-011	Monoclonal antibodies against HMGB1	11/974,923 10.15.07 Continuation of 10/938,992	Newman et al.
CTIP-017-US C2	3258.1033-012	Monoclonal antibodies against HMGB1	12/897,453 10.04.10 Continuation of 11/974,923	Newman et al.
	3258.1033-013 JAPAN DIV	Monoclonal antibodies against HMGB1	2011-118559 09.10.04 Divisional of 2006-526305	Newman et al.
CTIP-037-P1	3258.1040-000	Treatment of inflammatory skin conditions using antagonist of HMGB1	60/700,704 07.18.05	Marchini et al
CTIP-037-PCT	3258.1040-002	Treatment of inflammatory skin conditions using antagonist of HMGB1	PCT/US2006/027503 07.11.06	Marchini et al.
CTIP-037-US	3258.1040-003	Treatment of inflammatory skin conditions using antagonist of HMGB1	11/988,896 National Stage entry of PCT/US2006/027503 07.11.06	Marchini et al.
CTIP-037-EP	3258.1040-004 EUROPE	Treatment of inflammatory skin conditions using antagonist of HMGB1	EP 06 800 051.1 National Stage entry of PCT/US2006/027503 07.11.06	Marchini et al.